Monday, April 2, 2012
During oral arguments on the
Affordable Care Act at the Supreme Court, attention focused on the
constitutionality of the individual mandate to buy health insurance. But for
biopharma, what is at stake are provisions that directly affect the industry.
These include the biosimilars
pathway at FDA; the rebates and fees the industry already is paying in exchange
for a bigger population of insured patients; and the Independent Payment Advisory
Board, which would have broad powers to curtail Medicare spending.